Member Info for 13thmonkey

Unit tested in the UK in Acciona's presence. Similar operating temps to normal Spain I imagine.
https://twitter.com/AFCEnergy/status/1549759726074077184?s=20&t=f-UOVqX2PRo907PElBayqw

So is cave the CEO of nanosynth?

Do you want to try the end of that sentence again, it makes no sense.

So just useful for cancer in appendages?

Understand that, but even if another mechanism for targeting comes in from left field (and it would be a very narrow part of left field as everyone else in that part of the field has failed) that'll impact one companies portfolio of drugs as they would buy it to prevent their competitors from having access, that leaves us offering to the remainder.
Lets war game that a bit further:
a) Competitor comes from a big pharma, no one else gets access, they would all want their own version, Avacta wins.
b) Competitor comes from a small pharma, gets bought by big pharma, the others want their own version, Avacta wins.
c) Competitor comes from a small pharma, refuses buy out, offers at market licencing costs, big pharma would want an in-house version to control current and future costs, Avacta wins.
d) Competitor comes from a small pharma, refuses buy out, offers at very cheap licensing costs for the good of humanity, big pharma may not want an in-house version to control current and future costs, Avacta loses.

Option D is so unlikely as the cost to develop would have been high for a private company and hence they would act like option C, and high for a public company that shareholders would want a return and it would act like option C. The only way that this can take place is if some philanthropist is bank rolling it and does not want a return on the investment.

Which leaves a novel non FAP approach, something like what portege (?sp?) are doing, the one that Quint is banking on, they are one trick pony, it's a new approach and therefore will need more testing. I'd still suggest that the market is big enough for more than one approach.

Regardless, there's market enough for more than one solution. If some other company also reaches a FAP activating/binding milestone then they might get bought out, at which point the remaining big pharma players will want their own version for their own impending patent cliffs, there'd still be a bidding war, possibly earlier than if we were the sole player.

Unfortunately what's needed is some kind of mild outbreak of something to prove that it is useful, to allow the organisers to something that they would not have otherwise been able to do, or would not have been able to so so well/cheaply.
This may then lead to it staying in place afterwards, and the recurring revenues that would bring and the logical expansion.
Jurado, I think that countries are looking to have this all of the time, but it's new, the benefits are novel, that takes time. We've got limited capacity, so out of this as a showcase, or 'a part of a major city' i'd want this.

There's literally a running total under director dealings in the views at the top of the page.
However, that's just what he's brought, during house-gate wasn't the consensus amongst non-trolls that he had many multiples of what he's brought due to him should certain targets be met? So whilst he might own 470k (ish), there are more that are due to him which might be the more important question.

So he's suggesting that you can just get better if you eat better? So if you don't get better then you, the ill person, are to blame. What a twunt.

Salmon is about £20/kg

Scrap that, the units are MW not MWh

28MWh is 28MW for 1 hour, or 6MW generating for 4.6hrs per day. So the current array can easily achieve that, just over 1hr either side of each tide.

'deserve' what kind of language is that? You deserve to lead hallowed institutions, football clubs, household names. Not a small AIM listed company.

Very excitable

Even if it is expressed lightly elsewhere, that's much much better than straight doxyrubicin which doesn't have a trigger.

Been there, done that, interesting tech, needs gov with appropriate vision.

All not ask

I don't think that Aldebran has made a positive comment on any stock, ever. That's probably ask you need to know.

Understanding that there are known bad actors is important, if you see one of their comments start to be repeated as fact then you know how to deal with it.
Have no issue with challenge, but this was never about a valid alternative viewpoint.

I think that general market conditions are more to blame, Aim down 30+% from recent highs.